Bedfont Scientific Ltd. and NewMed Ltd. Proudly Raise Over £28,000 in Funds for Heart of Kent Hospice

Biogen ends agreement with Acorda for multiple sclerosis drug Fampyra

Biogen is handing back ex-US commercialization rights to Acorda Therapeutics for the multiple sclerosis drug Fampyra. Acorda will have the drug in-house effective Jan. 1,

January 12, 2024

Exercise boosts beneficial hormone transfer in breastfeeding mothers

Although women have breastfed since the beginning of time, there is very little scientific research on how exercise affects breast milk.

April 12, 2024

Regeneron and Mammoth team up to develop gene editing therapies

Share this article The CRISPR-based gene editing therapies will target multiple tissues and cell types. Credit: Anusorn Nakdee via Shutterstock. Regeneron Pharmaceuticals has collaborated with

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.